

**AUGUST 2018 PBAC MEETING – POSITIVE RECOMMENDATIONS**

DRUG, SPONSOR, TYPE OF SUBMISSION	DRUG TYPE OR USE	LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION	PBAC OUTCOME
<p>BUDESONIDE WITH EFOMOTEROL, Powder for oral inhalation in breath actuated device containing budesonide 200 micrograms with eformoterol fumarate dehydrate 6 micrograms per dose, 120 doses;</p> <p>Powder for oral inhalation in breath actuated device containing budesonide 400 micrograms with eformoterol fumarate dehydrate 12 micrograms per dose, 2 x 60 doses</p> <p>DuoResp® Spiromax®, Teva Pharma Australia Pty Ltd</p> <p>Symbicort Turbuhaler®, AstraZeneca Pty Ltd</p>	<p>Asthma COPD</p>	<p>To amend the restrictions for:</p> <ul style="list-style-type: none"> <li>•200/6: asthma (both brands);</li> <li>•400/12: asthma and COPD (both brands)</li> </ul> <p>So that both products have the same Authority Required (Streamlined) code.</p>	<p>The PBAC recommended amending the currently listed budesonide with formoterol 200/6 and 400/12 restrictions for asthma and chronic obstructive pulmonary disease (COPD) to enable these restrictions to have identical Authority Required (Streamlined) codes.</p> <p>See also November 2017 PBAC outcomes.</p>
<p>MENINGOCOCCAL POLYSACCHARIDE SEROGROUPS A, C, W-135 AND Y CONJUGATE VACCINE</p> <p>Injection 0.5 mL in pre-filled syringe</p> <p>Nimenrix®</p> <p>Pfizer Australia Pty Ltd</p> <p>Further consideration (Major Submission)</p>	<p>Meningococcal disease</p>	<p>To consider a revised proposal for request listing on the National Immunisation Program (NIP) for the immunisation of adolescents in Year 10 and a catch-up program for adolescents aged up to 19 years administered via a school or GP-based catch up program.</p>	<p>The PBAC revised its March 2018 recommendation for meningococcal polysaccharide serogroups A, C, W135 and Y conjugate vaccine (MenACWY-TT) and advised that the MenACWY-TT vaccine would be acceptably cost-effective at a price that results in a cost/QALY gained of \$15,000-45,000 or less would be acceptable in the context of the relatively small cost of the primary program.</p> <p>See also March 2018 PBAC outcomes.</p>